131 related articles for article (PubMed ID: 8646368)
1. Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature-gradient gel electrophoresis.
Riethdorf L; Begemann C; Riethdorf S; Milde-Langosch K; Löning T
Virchows Arch; 1996 Apr; 428(1):47-51. PubMed ID: 8646368
[TBL] [Abstract][Full Text] [Related]
2. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis.
Sherman ME; Bur ME; Kurman RJ
Hum Pathol; 1995 Nov; 26(11):1268-74. PubMed ID: 7590703
[TBL] [Abstract][Full Text] [Related]
3. Computerized image analysis of p53 and proliferating cell nuclear antigen expression in benign, hyperplastic, and malignant endometrium.
Elhafey AS; Papadimitriou JC; El-Hakim MS; El-Said AI; Ghannam BB; Silverberg SG
Arch Pathol Lab Med; 2001 Jul; 125(7):872-9. PubMed ID: 11419970
[TBL] [Abstract][Full Text] [Related]
4. Utility of Ki-67, p53, Bcl-2, and Cox-2 biomarkers for low-grade endometrial cancer and disordered proliferative/benign hyperplastic endometrium by imprint cytology.
Apostolou G; Apostolou N; Biteli M; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2014 Feb; 42(2):134-42. PubMed ID: 23729350
[TBL] [Abstract][Full Text] [Related]
5. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53.
Ambros RA; Vigna PA; Figge J; Kallakury BV; Mastrangelo A; Eastman AY; Malfetano J; Figge HL; Ross JS
Cancer; 1994 Mar; 73(6):1686-92. PubMed ID: 8156496
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status.
Koshiyama M; Konishi I; Wang DP; Mandai M; Komatsu T; Yamamoto S; Nanbu K; Naito MF; Mori T
Virchows Arch A Pathol Anat Histopathol; 1993; 423(4):265-71. PubMed ID: 8236823
[TBL] [Abstract][Full Text] [Related]
7. Hysteroscopic and immunohistochemical findings in type I and type II endometrial carcinomas.
Maia H; Maltez A; Fahel P; Coutinho E
J Am Assoc Gynecol Laparosc; 2001 May; 8(2):222-30. PubMed ID: 11342729
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric cell cycle kinetics and quantitative measurement of c-erbB-2 and mutant p53 proteins in normal, hyperplastic, and malignant endometrial biopsies.
Eissa S; Abu Saada M; el-Sharkawy T
Clin Biochem; 1997 Apr; 30(3):209-14. PubMed ID: 9167896
[TBL] [Abstract][Full Text] [Related]
9. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas.
Nikaido T; Li SF; Shiozawa T; Fujii S
Cancer; 1996 Sep; 78(6):1248-53. PubMed ID: 8826947
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
[TBL] [Abstract][Full Text] [Related]
11. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
12. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer.
Lisboa BW; Vogtländer S; Gilster T; Riethdorf L; Milde-Langosch K; Löning T
Virchows Arch; 1997 Dec; 431(6):375-81. PubMed ID: 9428925
[TBL] [Abstract][Full Text] [Related]
13. Patterns of immunohistochemical staining for p53 expression in hyperplastic endometrium and adenocarcinoma.
Terlikowski S; Lenczewski A; Famulski W; Sulkowska M; Dobrzycka B; Stasiuk-Barmuta A; Kulikowski M
Folia Histochem Cytobiol; 2001; 39 Suppl 2():195-6. PubMed ID: 11820604
[TBL] [Abstract][Full Text] [Related]
14. Abnormal expression of cripto and p53 protein in endometrial carcinoma and its precursor lesions.
Ayhan A; Tuncer ZS; Ruacan S; Ayhan A; Yasui W; Tahara E
Eur J Gynaecol Oncol; 1998; 19(3):316-8. PubMed ID: 9641241
[TBL] [Abstract][Full Text] [Related]
15. Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance.
Sivridis E; Giatromanolaki A; Koukourakis MI; Georgiou L; Anastasiadis P
Histopathology; 2002 Jan; 40(1):92-100. PubMed ID: 11903603
[TBL] [Abstract][Full Text] [Related]
16. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
17. Patterns of immunohistochemical staining for proliferating cell nuclear antigen and p53 in benign and neoplastic human endometrium.
Yu CC; Wilkinson N; Brito MJ; Buckley CH; Fox H; Levison DA
Histopathology; 1993 Oct; 23(4):367-71. PubMed ID: 7905459
[TBL] [Abstract][Full Text] [Related]
18. bcl-2 protein expression in endometrial carcinoma: the lack of correlation with p53.
Miturski R; Semczuk A; Tomaszewski J; Jakowicki J
Cancer Lett; 1998 Nov; 133(1):63-9. PubMed ID: 9929161
[TBL] [Abstract][Full Text] [Related]
19. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance.
Kato N; Watanabe J; Jobo T; Nishimura Y; Fujisawa T; Kamata Y; Kuramoto H
J Cancer Res Clin Oncol; 2003 Apr; 129(4):222-6. PubMed ID: 12684894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
